BACK
Kylor Hua
Executive Director
New York Office | kylor.hua@torreya.com | 212.257.5817
Kylor Hua, an Executive Director at Torreya, advises clients on strategic transactions in the US and Asia.
He joined Torreya in 2013, having previously worked as a summer analyst at the firm.
Kylor received a B.A., magna cum laude from the University of Rochester. He holds double majors in economics and business strategy, and brain and cognitive science, and a minor in Japanese. He is fluent in Mandarin and Japanese.
Selected Transactions
|
| Sale to |
|
|
$260 million
August 2021
|
|
| Acquisition of |
|
|
$225 million
September 2020
|
|
| Acquisition of generics business of |
|
|
$1.05 billion
June 2017
|
|
| Sale of Intrathecal business to |
|
|
$203 million
March 2017
|
|
| Company sale to |
|
|
$100+ million
December 2015
|
|
| Acquired by |
|
|
August 2021
|
|
| Co-advisor on direct public offering |
|
|
$15 million
August 2020
|
|
|
| Strategic investment from |
|
|
$30 million
February 2020
|
|
| JV Partnership in China with |
|
|
$50 million
December 2018
|
|
| Sale of Sevelamer ANDA to |
|
|
October 2018
|
|
| Debt recapitalization and acquisition of NextWave Pharmaceuticals from |
|
|
$125 million
September 2018
|
|
| License of AJT-240 in hemodialysis in China to |
|
|
Up to $24 million
June 2018
|
|
| Sale of consumer products to |
|
|
February 2018
|
|
|
| Sale of ANDA portfolio to |
|
|
January 2018
|
|
| Sale to |
|
|
Up to $34 million
November 2017
|
|
|
| Sale of generics portfolio to |
|
|
$18 million
August 2017
|
|
| Sale of company to |
|
|
June 2017
|
|
| Merger with |
|
|
$251 million
December 2016
|
|
| Collaboration agreement for Emricasan with |
|
|
$50 million upfront
December 2016
|
|
|
| Sale of ANDA portfolio to |
|
|
|
October 2016
|
|
| Sale of abbreviated new drug applications |
|
|
February 2016
|
|
| Sale of assets to |
|
|
$10 million
February 2016
|
|
| Acquisition of |
|
|
CAD $47 million
October 2015
|
|
| License of global rights for Anti-TGF-beta antibody program to |
|
|
|
Up to $517 million
October 2015
|
|
| Sale of abbreviated new drug application portfolio to |
|
|
|
$25 million +
profit share July 2015
|
|
|
| Sale of Zonalon® to |
|
|
March 2015
|
|
|
| Divestiture of certain abbreviated new drug applications to |
|
|
Up to $18 million
October 2014
|
|
| Acquisition of Donnatal® from |
|
|
$328 million
May 2014
|